Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LDLR | P01130 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802440 | 0.91 | CNR2 (0.48) | CNR2ACHEHTR4KMT2AALDH1A1 | |
| SCHEMBL23801792 | 0.89 | KMT2A (0.46) | CNR2ACHEHTR4NPC1KMT2A | |
| SCHEMBL23802437 | 0.82 | CNR2 (0.47) | CNR2ACHEKMT2AALDH1A1MEN1 | |
| SCHEMBL25515703 | 0.81 | CNR2 (0.45) | CNR2ACHEHTR4ALDH1A1THRB | |
| SCHEMBL23802426 | 0.78 | TUBB4A (0.44) | CNR2NPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL25516686 | 0.75 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL25517133 | 0.75 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL23801793 | 0.74 | CNR2 (0.39) | CNR2ACHEHTR4KMT2AALDH1A1 | |
| SCHEMBL22534544 | 0.74 | CNR2 (0.46) | CNR2ACHEHTR4NPC1KMT2A | |
| SCHEMBL21610323 | 0.73 | NPC1 (0.53) | CNR2ACHENPC1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | CNR2 663/4885ACHE 1821/4885HTR4 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.